Trial Profile
A Multicenter Open-label Extension Study To Assess Long-term Safety Of PF-00547659 In Subjects With Crohn's Disease OPERA II
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2022
Price :
$35
*
At a glance
- Drugs Ontamalimab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Acronyms OPERA II
- Sponsors Pfizer; Shire
- 24 Oct 2018 Results assessing Long Term Safety, Efficacy and Pharmacokinetics of Shp647 in Crohn's Disease, presented at the 26th United European Gastroenterology Week.
- 10 Oct 2018 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2018
- 30 Aug 2016 Status changed from active, no longer recruiting to completed.